Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

Fig. 2

ONC201 acts in combination with murine VEGF inhibitors and anti-angiogenic agent regorafenib in vivo to suppress tumor growth. a Final tumor measurements of HCT116 xenografts with ONC201 or the indicated combinations after 3 weeks. b Light microscopy and fluorescent GFP images of metastases in vehicle, regorafenib, and ONC201 treated mice. c Relative tumor growth of MC38 tumors in C57/BL6 mice after 4 weeks. ONC201: 50 mg/kg every week. Regorafenib: 5 mg/kg daily. Bevacizumab: 5 mg/kg every other week. N = 5

Back to article page